67Cu-SARbisPSMA)) is a new PSMA targeting drug labeled with 67Cu and developed by the Australian company Clarity Pharmaceuticals as therapeutic analogue of 64Cu-SARbisPSMA. The first US Phase I/II clinical trial involving both 64Cu/67Cu-SARbisPSMA Phase I/II trial is expected to start inclusion before end of the year 2021

Target/Mechanism: PSMA

Leading Emitter: beta electrons (β)